AMG 598 / Amgen - LARVOL DELTA

Multiple Ascending Dose Study of AMG 598 in Subjects With Obesity (clinicaltrials.gov) - P1b; N=108; Recruiting; Sponsor: Amgen; Not yet recruiting ➔ Recruiting

Enrollment open • Biosimilar • Metabolic Disorders • Obesity

Multiple Ascending Dose Study of AMG 598 in Subjects With Obesity (clinicaltrials.gov) - P1b; N=50; Completed; Sponsor: Amgen; Active, not recruiting ➔ Completed; Trial primary completion date: Aug 2019 ➔ Dec 2019

Clinical • Trial completion • Trial primary completion date

Multiple Ascending Dose Study of AMG 598 in Subjects With Obesity (clinicaltrials.gov) - P1b; N=50; Active, not recruiting; Sponsor: Amgen; Recruiting ➔ Active, not recruiting; N=108 ➔ 50; Trial primary completion date: Dec 2019 ➔ Aug 2019

Clinical • Enrollment change • Enrollment closed • Trial primary completion date